Abstract
Alterated cytokine secretion may play a role in determining Hodgkin's disease-related immunosuppression. The aim of this study was to analyze the clinical significance of interleukin-10 (IL-10) serum levels in 73 chemotherapy-naive patients with Hodgkin's disease. We evaluated the relationship between pretreatment circulating values of IL-10 and both the clinical characteristics of the disease as well as the prognosis in terms of freedom from progression and overall survival. Abnormally high pre-treatment serum levels (mean ± standard error: 26.79 ± 13.24 pg/ml) were detected in 33/73 (45%) patients. The percentage of patients with enhanced IL-10 secretion was significantly higher in the presence of advanced disease (56% vs 32%, P <0.03), systemic symptoms (57% vs 34%, P <0.04) and more than 3 involved sites (61% vs 36%, P <0.03). The high basal levels of IL-10 negatively influenced long-term results: at 8-years freedom from progression (FFP) and overall survival (OS) for patients with IL-10>6 pg/ml vs ≤ 6 pg/ml were 69% and 76% vs 97.5% and 95%, respectively. The multivariate analysis confirmed the prognostic value of IL-10 basal serum levels (FFP, P= 0.0001; OS, P= 0.06). Our study suggests that high pre-treatment circulating levels of IL-10 are associated with a poor prognosis, irrespective of other common prognostic variables.
| Original language | English |
|---|---|
| Pages (from-to) | 59-63 |
| Number of pages | 5 |
| Journal | Medical Oncology |
| Volume | 17 |
| Issue number | 1 |
| Publication status | Published - 2000 |
Fingerprint
Keywords
- Citokines
- Hodgkin's disease
- IL-10
- Malignant lymphomas
- Outcome
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience. / Viviani, Simonetta; Notti, P.; Bonfante, V.; Verderio, P.; Valagussa, P.; Bonadonna, G.
In: Medical Oncology, Vol. 17, No. 1, 2000, p. 59-63.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience
AU - Viviani, Simonetta
AU - Notti, P.
AU - Bonfante, V.
AU - Verderio, P.
AU - Valagussa, P.
AU - Bonadonna, G.
PY - 2000
Y1 - 2000
N2 - Alterated cytokine secretion may play a role in determining Hodgkin's disease-related immunosuppression. The aim of this study was to analyze the clinical significance of interleukin-10 (IL-10) serum levels in 73 chemotherapy-naive patients with Hodgkin's disease. We evaluated the relationship between pretreatment circulating values of IL-10 and both the clinical characteristics of the disease as well as the prognosis in terms of freedom from progression and overall survival. Abnormally high pre-treatment serum levels (mean ± standard error: 26.79 ± 13.24 pg/ml) were detected in 33/73 (45%) patients. The percentage of patients with enhanced IL-10 secretion was significantly higher in the presence of advanced disease (56% vs 32%, P <0.03), systemic symptoms (57% vs 34%, P <0.04) and more than 3 involved sites (61% vs 36%, P <0.03). The high basal levels of IL-10 negatively influenced long-term results: at 8-years freedom from progression (FFP) and overall survival (OS) for patients with IL-10>6 pg/ml vs ≤ 6 pg/ml were 69% and 76% vs 97.5% and 95%, respectively. The multivariate analysis confirmed the prognostic value of IL-10 basal serum levels (FFP, P= 0.0001; OS, P= 0.06). Our study suggests that high pre-treatment circulating levels of IL-10 are associated with a poor prognosis, irrespective of other common prognostic variables.
AB - Alterated cytokine secretion may play a role in determining Hodgkin's disease-related immunosuppression. The aim of this study was to analyze the clinical significance of interleukin-10 (IL-10) serum levels in 73 chemotherapy-naive patients with Hodgkin's disease. We evaluated the relationship between pretreatment circulating values of IL-10 and both the clinical characteristics of the disease as well as the prognosis in terms of freedom from progression and overall survival. Abnormally high pre-treatment serum levels (mean ± standard error: 26.79 ± 13.24 pg/ml) were detected in 33/73 (45%) patients. The percentage of patients with enhanced IL-10 secretion was significantly higher in the presence of advanced disease (56% vs 32%, P <0.03), systemic symptoms (57% vs 34%, P <0.04) and more than 3 involved sites (61% vs 36%, P <0.03). The high basal levels of IL-10 negatively influenced long-term results: at 8-years freedom from progression (FFP) and overall survival (OS) for patients with IL-10>6 pg/ml vs ≤ 6 pg/ml were 69% and 76% vs 97.5% and 95%, respectively. The multivariate analysis confirmed the prognostic value of IL-10 basal serum levels (FFP, P= 0.0001; OS, P= 0.06). Our study suggests that high pre-treatment circulating levels of IL-10 are associated with a poor prognosis, irrespective of other common prognostic variables.
KW - Citokines
KW - Hodgkin's disease
KW - IL-10
KW - Malignant lymphomas
KW - Outcome
UR - http://www.scopus.com/inward/record.url?scp=0034059443&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034059443&partnerID=8YFLogxK
M3 - Article
C2 - 10713662
AN - SCOPUS:0034059443
VL - 17
SP - 59
EP - 63
JO - Medical Oncology
JF - Medical Oncology
SN - 1357-0560
IS - 1
ER -